These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 17634482)
1. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482 [TBL] [Abstract][Full Text] [Related]
2. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022 [TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. Laurie SA; Gauthier I; Arnold A; Shepherd FA; Ellis PM; Chen E; Goss G; Powers J; Walsh W; Tu D; Robertson J; Puchalski TA; Seymour L J Clin Oncol; 2008 Apr; 26(11):1871-8. PubMed ID: 18398152 [TBL] [Abstract][Full Text] [Related]
4. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299 [TBL] [Abstract][Full Text] [Related]
5. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Yamamoto N; Tamura T; Yamamoto N; Yamada K; Yamada Y; Nokihara H; Fujiwara Y; Takahashi T; Murakami H; Boku N; Yamazaki K; Puchalski TA; Shin E Cancer Chemother Pharmacol; 2009 Nov; 64(6):1165-72. PubMed ID: 19308410 [TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956 [TBL] [Abstract][Full Text] [Related]
7. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Wedge SR; Kendrew J; Hennequin LF; Valentine PJ; Barry ST; Brave SR; Smith NR; James NH; Dukes M; Curwen JO; Chester R; Jackson JA; Boffey SJ; Kilburn LL; Barnett S; Richmond GH; Wadsworth PF; Walker M; Bigley AL; Taylor ST; Cooper L; Beck S; Jürgensmeier JM; Ogilvie DJ Cancer Res; 2005 May; 65(10):4389-400. PubMed ID: 15899831 [TBL] [Abstract][Full Text] [Related]
8. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467 [TBL] [Abstract][Full Text] [Related]
9. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535 [TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. van Cruijsen H; Voest EE; Punt CJ; Hoekman K; Witteveen PO; Meijerink MR; Puchalski TA; Robertson J; Saunders O; Jürgensmeier JM; van Herpen CM; Giaccone G Eur J Cancer; 2010 Mar; 46(5):901-11. PubMed ID: 20061136 [TBL] [Abstract][Full Text] [Related]
11. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900 [TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291 [TBL] [Abstract][Full Text] [Related]
14. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201 [TBL] [Abstract][Full Text] [Related]
15. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Rugo HS; Herbst RS; Liu G; Park JW; Kies MS; Steinfeldt HM; Pithavala YK; Reich SD; Freddo JL; Wilding G J Clin Oncol; 2005 Aug; 23(24):5474-83. PubMed ID: 16027439 [TBL] [Abstract][Full Text] [Related]
16. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547 [TBL] [Abstract][Full Text] [Related]
17. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650 [TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. Herbst RS; Hong D; Chap L; Kurzrock R; Jackson E; Silverman JM; Rasmussen E; Sun YN; Zhong D; Hwang YC; Evelhoch JL; Oliner JD; Le N; Rosen LS J Clin Oncol; 2009 Jul; 27(21):3557-65. PubMed ID: 19546406 [TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. Miller AA; Murry DJ; Owzar K; Hollis DR; Lewis LD; Kindler HL; Marshall JL; Villalona-Calero MA; Edelman MJ; Hohl RJ; Lichtman SM; Ratain MJ J Clin Oncol; 2007 Jul; 25(21):3055-60. PubMed ID: 17634483 [TBL] [Abstract][Full Text] [Related]
20. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. Langenberg MH; van Herpen CM; De Bono J; Schellens JH; Unger C; Hoekman K; Blum HE; Fiedler W; Drevs J; Le Maulf F; Fielding A; Robertson J; Voest EE J Clin Oncol; 2009 Dec; 27(36):6152-9. PubMed ID: 19901116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]